Cannabis Science Inc  

(Public, OTCMKTS:CBIS)   Watch this stock  
Find more results for PINK:CBIS
0.102
-0.003 (-2.39%)
Apr 24 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.10 - 0.11
52 week 0.03 - 0.30
Open 0.11
Vol / Avg. 3.88M/12.77M
Mkt cap 77.66M
P/E     -
Div/yield     -
EPS -0.01
Shares 761.32M
Beta 3.38
Inst. own 0%

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -1680.07% -43842.45%
Operating margin -1522.48% -45468.95%
EBITD margin - -14776.76%
Return on average assets -723.94% -2746.14%
Return on average equity - -
Employees 2 -
CDP Score - -

Address

Suite B #254, 6946 North Academy Blvd
COLORADO SPRINGS, CO 80918
United States - Map
+1-888-8890888 (Phone)

Description

Cannabis Science, Inc. is a development-stage company. Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. The Company is dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company is engaged in medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. On February 9, 2012, the Company acquired GGECO University, Inc. (GGECO). On March 21, 2012, the Company acquired Cannabis Consulting Inc. (CCI Group).

Officers and directors

Robert J. Melamede Ph.D. President, Interim Chief Financial Officer, Director
Age: 65
Dorothy Bray Ph.D. Chief Executive Officer, Director
Chad S. Johnson Esq. General Legal Counsel, Corporate Secretary, Director
Age: 45
Mario Lap Director